Tumorigenic effect of and its potential therapeutic target in NSCLC (Review).

Non‑small cell lung cancer (NSCLC), which accounts for ~85% of all lung cancer cases, is commonly diagnosed at an advanced stage and has a high patient mortality rate. Despite the increasing availability of treatment strategies, the prognosis of patients with NSCLC remains poor, with a low 5‑year survival rate. This poor prognosis may be associated with the tumor heterogeneity of NSCLC, as well as its acquisition and intrinsic resistance to therapeutic drugs. It has been suggested that combination therapy with telomerase inhibition may be an effective strategy for the treatment of drug‑sensitive and drug‑resistant types of cancer. Telomerase is the key enzyme for cell survival, and ~90% of human cancers maintain telomeres by activating telomerase, which is driven by the upregulation of telomerase reverse transcriptase (). Several mechanisms of telomerase reactivation have been described in a variety of cancer types, including promoter mutation, epigenetic modifications via a promoter, amplification, and rearrangement. The aim of the present study was to comprehensively review telomerase activity and its association with the clinical characteristics and prognosis of NSCLC, as well as analyze the potential mechanism via which activates telomerase and determine its potential clinical application in NSCLC. More importantly, current treatment strategies targeting in NSCLC have been summarized with the aim to promote discovery of novel strategies for the future treatment of NSCLC.